OTC:FPHAF Faron Pharmaceuticals Oy (FPHAF) Stock Price, News & Analysis $3.30 0.00 (0.00%) As of 05/12/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Faron Pharmaceuticals Oy Stock (OTC:FPHAF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get FPHAF alerts:Sign Up Key Stats Today's Range$3.30▼$3.3050-Day Range$3.30▼$3.3052-Week Range$3.10▼$6.00VolumeN/AAverage Volume3,650 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewFaron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. It also develops Haematokine, an investigational AOC3 inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. In addition, the company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.Read More… Receive FPHAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Faron Pharmaceuticals Oy and its competitors with MarketBeat's FREE daily newsletter. Email Address FPHAF Stock News HeadlinesFaron Pharmaceuticals Founders Donate and Sell Shares to Support Medical ResearchJune 5, 2025 | tipranks.comPromising Phase 2 Results and Regulatory Progress Drive Buy Rating for Faron Pharmaceuticals’ BexmarilimabJune 3, 2025 | tipranks.com379 passengers walked away from thisForget OpenAI, ChatGPT, and the $2 trillion chip race… The real story is buried inside a new U.S. patent. Elon Musk has already invested $51 million. And the company behind it may be sitting on the most important IP of the decade.June 22, 2025 | True Market Insiders (Ad)Faron Pharmaceuticals Converts Special Rights into Shares for Bond AmortisationJune 3, 2025 | tipranks.comFaron Pharmaceuticals Grants 876,000 Share Options to Directors and PersonnelMay 14, 2025 | tipranks.comPromising Clinical Data and Innovative Mechanism Drive Buy Rating for Faron Pharmaceuticals’ BEXMAB in MDS TreatmentMay 12, 2025 | tipranks.comFaron Pharmaceuticals Sees Increased Share Liquidity Following A&B DivestmentApril 17, 2025 | tipranks.comBuy Rating for Faron Pharmaceuticals: Promising Phase 2 Results and Strategic Growth PotentialApril 15, 2025 | tipranks.comSee More Headlines FPHAF Stock Analysis - Frequently Asked Questions How have FPHAF shares performed this year? Faron Pharmaceuticals Oy's stock was trading at $3.30 at the beginning of the year. Since then, FPHAF stock has increased by 0.0% and is now trading at $3.30. View the best growth stocks for 2025 here. How do I buy shares of Faron Pharmaceuticals Oy? Shares of FPHAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTC SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTC:FPHAF CIKN/A Webwww.faron.com Phone358.2.469.5151FaxN/AEmployees40Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (OTC:FPHAF) was last updated on 6/22/2025 by MarketBeat.com Staff From Our PartnersThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored379 passengers walked away from thisForget OpenAI, ChatGPT, and the $2 trillion chip race… The real story is buried inside a new U.S. patent. E...True Market Insiders | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Faron Pharmaceuticals Oy Please log in to your account or sign up in order to add this asset to your watchlist. Share Faron Pharmaceuticals Oy With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.